Atoxic derivative of botulinum neurotoxin a as a prototype molecular vehicle for targeted delivery to the neuronal cytoplasm

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Vazquez Cintron, Edwin J ^a   Vakulenko, Maksim ^a   Band, Philip A ^a,b   Stanker, Larry H ^c   Johnson, Eric A ^d   Ichtchenko, Konstantin ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NYU HOSPITAL FOR JOINT DISEASES   (United States)

^c WESTERN REGIONAL RESEARCH CENTER   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; DRUG VEHICLE; PRONASE; SNARE PROTEIN; SYNAPTOBREVIN 2; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; NEUROTOXIN; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ACTIVITY; CELL MEMBRANE; CELL MEMBRANE DEPOLARIZATION; CELL MIGRATION; CONTROLLED STUDY; CYTOPLASM; DRUG DELIVERY SYSTEM; EMBRYO; ENDOSOME; FEMALE; FLOW CYTOMETRY; HIPPOCAMPAL NEURONAL CULTURE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTERNALIZATION; INTRACELLULAR SPACE; LIGHT CHAIN; NERVE CELL; NONHUMAN; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RAT; WESTERN BLOTTING; ANIMAL; CELL CULTURE; CONFOCAL MICROSCOPY; CYTOLOGY; EMBRYOLOGY; ENDOCYTOSIS; GENETICS; HIPPOCAMPUS; METABOLISM; MUTATION; PROTEIN TRANSPORT; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; BLOTTING, WESTERN; BOTULINUM TOXINS, TYPE A; CELLS, CULTURED; CYTOPLASM; ENDOCYTOSIS; FEMALE; FLOW CYTOMETRY; HIPPOCAMPUS; MICROSCOPY, CONFOCAL; MUTATION; NEURONS; NEUROTOXINS; PROTEIN BINDING; PROTEIN TRANSPORT; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; VESICLE-ASSOCIATED MEMBRANE PROTEIN 2;

EID: 84899891773     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085517     Document Type: Article

References (42)

1. Johnson EA, Tepp WH, Bradshaw M, Gilbert RJ, Cook PE, et al. (2005) Characterization of Clostridium botulinum strains associated with an infant botulism case in the United Kingdom. J Clin Microbiol 43: 2602-2607. (Pubitemid 40827927)
2. Schiavo G, Matteoli M, Montecucco C (2000) Neurotoxins affecting neuroexocytosis. Physiol Rev 80: 717-766. (Pubitemid 30164948)
3. Simpson LL (2004) Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 44: 167-193.
4. Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, et al. (2005) Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun 73: 5450-5457. (Pubitemid 41192979)
5. Barash JR, Arnon SS (2013) A Novel Strain of Clostridium botulinum That Produces Type B and Type H Botulinum Toxins. J Infect Dis.
6. Dover N, Barash JR, Hill KK, Xie G, Arnon SS (2013) Molecular Characterization of a Novel Botulinum Neurotoxin Type H Gene. J Infect Dis.
7. Hill KK, Smith TJ (2013) Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes. Curr Top Microbiol Immunol 364: 1-20.
8. Dressler D (2012) Clinical applications of botulinum toxin. Curr Opin Microbiol 15: 325-336.
9. Sugawara Y, Matsumura T, Takegahara Y, Jin Y, Tsukasaki Y, et al. (2010) Botulinum hemagglutinin disrupts the intercellular epithelial barrier by directly binding E-cadherin. J Cell Biol 189: 691-700.
10. Fujinaga Y (2010) Interaction of botulinum toxin with the epithelial barrier. J Biomed Biotechnol 2010: 974943.
11. Jahn R, Scheller RH (2006) SNAREs-engines for membrane fusion. Nat Rev Mol Cell Biol 7: 631-643.
12. Montal M (2010) Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem 79: 591-617.
13. Simpson LL, Maksymowych AB, Park JB, Bora RS (2004) The role of the interchain disulfide bond in governing the pharmacological actions of botulinum toxin. J Pharmacol Exp Ther 308: 857-864. (Pubitemid 38263958)
14. Johnson EA (1999) Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. Annu Rev Microbiol 53: 551-575.
15. Montecucco C, Schiavo G (1994) Mechanism of action of tetanus and botulinum neurotoxins. Mol Microbiol 13: 1-8. (Pubitemid 24220537)
16. Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, et al. (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312: 592-596.
17. Mahrhold S, Rummel A, Bigalke H, Davletov B, Binz T (2006) The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett 580: 2011-2014.
18. Gibert M, Marvaud JC, Pereira Y, Hale ML, Stiles BG, et al. (2007) Differential requirement for the translocation of clostridial binary toxins: iota toxin requires a membrane potential gradient. FEBS Lett 581: 1287-1296. (Pubitemid 46452601)
19. Keller JE, Neale EA, Oyler G, Adler M (1999) Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett 456: 137-142. (Pubitemid 29339056)
20. Fischer A, Montal M (2007) Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J Biol Chem 282: 29604-29611. (Pubitemid 350043363)
21. Fischer A, Montal M (2007) Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes. Proc Natl Acad Sci U S A 104: 10447-10452. (Pubitemid 47185685)
22. Band PA, Blais S, Neubert TA, Cardozo TJ, Ichtchenko K (2010) Recombinant derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal delivery. Protein Expr Purif 71: 62-73.
23. Pellett S, Tepp WH, Stanker LH, Band PA, Johnson EA, et al. (2011) Neuronal targeting, internalization, and biological activity of a recombinant atoxic derivative of botulinum neurotoxin A. Biochem Biophys Res Commun 405: 673-677.
24. Vicario-Abejon C (2004) Long-term culture of hippocampal neurons. Curr Protoc Neurosci Chapter 3: Unit 3 2.
25. Stanker LH, Merrill P, Scotcher MC, Cheng LW (2008) Development and partial characterization of high-affinity monoclonal antibodies for botulinum toxin type A and their use in analysis of milk by sandwich ELISA. J Immunol Methods 336: 1-8.
26. Scotcher MC, McGarvey JA, Johnson EA, Stanker LH (2009) Epitope characterization and variable region sequence of f1-40, a high-affinity monoclonal antibody to botulinum neurotoxin type a (Hall strain). PLoS One 4: e4924.
27. Cheng LW, Stanker LH, Henderson TD 2nd, Lou J, Marks JD (2009) Antibody protection against botulinum neurotoxin intoxication in mice. Infect Immun 77: 4305-4313.
28. Wessel D, Flugge UI (1984) A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem 138: 141-143. (Pubitemid 14146660)
29. Francis JW, Hosler BA, Brown RH Jr, Fishman PS (1995) CuZn superoxide dismutase (SOD-1):tetanus toxin fragment C hybrid protein for targeted delivery of SOD-1 to neuronal cells. J Biol Chem 270: 15434-15442.
30. Ascoli GA (2006) Mobilizing the base of neuroscience data: the case of neuronal morphologies. Nat Rev Neurosci 7: 318-324.
31. Ishizuka N, Cowan WM, Amaral DG (1995) A quantitative analysis of the dendritic organization of pyramidal cells in the rat hippocampus. J Comp Neurol 362: 17-45.
32. Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, et al. (1993) Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 365: 160-163. (Pubitemid 23282061)
33. Brewer GJ, Torricelli JR, Evege EK, Price PJ (1993) Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J Neurosci Res 35: 567-576. (Pubitemid 23215708)
34. Bade S, Rummel A, Reisinger C, Karnath T, Ahnert-Hilger G, et al. (2004) Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates. J Neurochem 91: 1461-1472. (Pubitemid 39658572)
35. Goodnough MC, Oyler G, Fishman PS, Johnson EA, Neale EA, et al. (2002) Development of a delivery vehicle for intracellular transport of botulinum neurotoxin antagonists. FEBS Lett 513: 163-168. (Pubitemid 34251257)
36. Ho M, Chang LH, Pires-Alves M, Thyagarajan B, Bloom JE, et al. (2011) Recombinant botulinum neurotoxin A heavy chain-based delivery vehicles for neuronal cell targeting. Protein Eng Des Sel 24: 247-253.
37. Singh BR, Thirunavukkarasu N, Ghosal K, Ravichandran E, Kukreja R, et al. (2010) Clostridial neurotoxins as a drug delivery vehicle targeting nervous system. Biochimie 92: 1252-1259.
38. Zhang P, Ray R, Singh BR, Li D, Adler M, et al. (2009) An efficient drug delivery vehicle for botulism countermeasure. BMC Pharmacol 9: 12.
39. Brunger AT, Breidenbach MA, Jin R, Fischer A, Santos JS, et al. (2007) Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain. PLoS Pathog 3: 1191-1194. (Pubitemid 47510272)
40. Koriazova LK, Montal M (2003) Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol 10: 13-18. (Pubitemid 36034171)
41. Kuo CL, Oyler GA, Shoemaker CB (2011) Accelerated neuronal cell recovery from Botulinum neurotoxin intoxication by targeted ubiquitination. PLoS One 6: e20352.
42. Sanders JD, Yang Y, Liu Y (1998) Differential turnover of syntaxin and SNAP-25 during synaptogenesis in cultured cerebellar granule neurons. J Neurosci Res 53: 670-676. (Pubitemid 28423875)